Sub menu

 

 

UCB Australia Pty Ltd

Regulatory activities for this sponsor.

Type

Date

13 result(s) found, displaying 1 to 10

  • ZILBRYSQ

    Australian public assessment report (AusPar)
    ZILBRYSQ (zilucoplan) is an add-on to standard therapy for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor-antibody positive.

  • Zilbrysq (zilucoplan)

    Prescription medicine decision summary
    Zilbrysq (zilucoplan) has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.

  • AusPAR: Lacosamide

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Lacosamide

  • AusPAR: Certolizumab pegol

    Australian public assessment report (AusPar)
    Australian Public Assessment for Certolizumab pegol

  • AusPAR: Brivaracetam

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brivaracetam

  • AusPAR: Certolizumab pegol (rbe)

    Australian public assessment report (AusPar)
    Australian public assessment report for Certolizumab pegol (rbe)